【摘要】 目的探讨非小细胞肺癌患者手术前后血清可溶性Fas(solubleFas,sFas)和FasL(sol-ubleFasL,sFasL)水平的变化及其临床意义。方法采用双抗体夹心酶联免疫吸附法检测52名健康人以及86例非小细胞肺癌患者血清中sFas和sFasL的水平,并检测其中手术治疗的68例患者手术前、手术后2周和手术后半年sFas和sFasL水平的变化。结果非小细胞肺癌患者血清中sFas(t=15·2238,P<0·01)和sFasL(t’=35·817,P<0·01)的水平与健康对照组相比差异有统计学意义;非小细胞肺癌患者血清中sFas和sFasL的水平与患者年龄(t=1·1824,P>0·05;t’=0·9407,P>0·05)、性别(t=1·3118,P>0·05;t=1·3698,P>0·05)和组织学分型(t=1·1458,P>0·05;t=1·6294,P>0·05)均无相关性;非小细胞肺癌Ⅳ期患者血清中sFas、sFasL的水平明显高于Ⅲ期(q=8·2220,P<1·01;q=7·5416,P<0·01)、Ⅱ期(q=12·7825,P<0·01;q=0·9324,P<0·01)和Ⅰ期(q=18·2960,P<0·01;q=11·8924,P<0·01);Ⅲ期明显高于Ⅱ期(q=8·0707,P<0·01;q=3·1764,P<0·05)和Ⅰ期(q=16·3315,P<0·01;q=7·6616,P<0·01);Ⅱ期明显高于Ⅰ期(q=7·1353,P<0·01;q=3·8536,P<0·01);非小细胞肺癌患者手术后2周血清sFas的水平明显低于手术前,P<0·05;而sFasL的水平差异无统计学意义,P>0·05。手术半年后血清sFas(P<0·01)和sFasL(P<0·01)的水平均明显低于手术前。结论sFas和sFasL的产生与肿瘤相关。sFas和sFasL可能为非小细胞肺癌诊断和手术疗效的指标。更多还原

【Abstract】 OBJECTIVE:To study the changes of serum soluble Fas（sFas） and soluble Fas ligand（sFasL） levels in patients with non-small cell lung cancer before and after surgical treatment and evaluate their clinical values. METHODS: Serum levels of sFas and sFasL were determined by double antibody sandwich ELISA （Enzyme linked immunosorbenl assays） in samples taken from both 86 cases （46 cases of squmous cell carcinoma and 40 cases adenocarcinoma） of non-small cell lung cancer and in samples taken from 52 cases of healthy volunteers. Among the 86 patients, 68 cases treated by surgery were checked on the day before surgery （T₀）,and 2 weeks （T₁） and 6 months after surgery （T₂） respectively. RESULTS: The serum levels of sFas （t=15.223 8,P<0.01） and sFasL （t’=35.817,P<0.01） in non-small cell lung cancer were significantly higher than those in the normal control,and were not related to age （t=1.182 4,P>0.05;t’=0.940 7,P>0.05）,sex （t=1.311 8, P>0.05;t=1.369 8,P>0.05） and pathologic types （t=1.145 8,P>0.05;t=1.629 4,P>0.05）; the serum levels of sFas and sFasL in stage Ⅳ were higher in comparision with stage Ⅲ （q=8.222 0,P<0.01;q=7.541 6,P<0.01）,stageⅡ （q=12.782 5, P<0.01;q= 8.932 4 ,P<0.01） and stage Ⅰ （q=18.296 0, P<0.01;q=11.892 4,P<0.01）. In stage Ⅲ, they were higher than those in stage Ⅱ （q=8.070 7,P<0.01;q=3.176 4,P<0.05） and stage Ⅰ （q=16.331 5, P<0.01;q=7.661 6,P<0.01）, and in stage Ⅱ, they were higher than those in stage Ⅰ （q=7.135 3, P< 0.01;q=3.853 6,P<0.01） After surgery there was a statistically significant decrease in sFas at both T₁（P<0.05） and T₂（P<0.01）,and in sFasL at T₂, P<0.01. CONCLUSIONS: The decrease in levels of sFas and sFasL after surgery suggests that they may be produced by or closely linked to tumour cells. Detection of the levels of sFas and sFasL may play an important role for cancer therapy and predict prognosis in non-small cell lung cancer.更多还原